Printed From:

Proven outcomes in UA/NSTEMI and STEMI

UA/NSTEMI

LOVENOX significantly reduced the incidence of the combined endpoint of death, MI, or recurrent angina versus unfractionated heparin (UFH) in UA/NSTEMI patients when administered concomitantly with aspirin.

Relative risk reduction in patient's clinical study results

ARR=absolute risk reduction; NNT=number needed to treat; RRR=relative risk reduction

aThe NNT and the benefit/risk profile were not prespecified analyses in the trials and were calculated using the reported ARR results.3

Prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction

Patients with recent unstable angina or non-Q-wave MI were treated with either LOVENOX 1 mg/kg  subcutaneously q12h or heparin. A total of 3,107 patients, ranging in age from 25 to 94 years (median age 64 years) were treated. All patients also received aspirin 100 mg to 325 mg per day. The combined incidence of the triple endpoint of death, MI, or recurrent angina was lower with LOVENOX versus heparin therapy at 14 days and sustained up to 30 days, after initiation of treatment.

Major bleeding episodes occurred in 1% of patients in each treatment group.


Lowered ischemia in
the ESSENCE study

In ESSENCE, LOVENOX provided early and long-term efficacy in ischemic events vs UFH.

Proven efficacy in combined end point of reducing death, MI, and recurrent angina vs UFH clinical study results

The combined incidence of death or myocardial infarction at all time points was lower for LOVENOX compared to standard heparin therapy, but did not achieve statistical significance.

  • Urgent revascularization procedures were performed less frequently in the LOVENOX group as compared to the heparin group1
  • At 30 days, major bleeds were comparable (6.5% LOVENOX vs 7.0% UFH; P=NS); overall bleeding for LOVENOX was higher vs UFH (18.4% vs 14.2%, respectively; P=0.001)2

Need for intervention was significantly lower with LOVENOX vs UFH


Serious adverse events occurring at ≥0.5% incidence in Lovenox-treated patients with unstable angina or non-Q-wave myocardial infarction
 
LOVENOX
(%)
Heparin
(%)
Atrial fibrillation
11 (0.70)
3 (0.20)
Heart failure
15 (0.95)
11 (0.72)
Lung edema
11 (0.70)
11 (0.72)
Pneumonia
13 (0.82)
9 (0.59)


UA/NSTEMI
guideline

2014 AHA/ACC Guidelines on the management of patients with non-STEMI ACS recommends the use of enoxaparin for initial anticoagulant therapy.5


STEMI

LOVENOX reduced the rate of the combined endpoint of recurrent myocardial infarction (MI) or death in patients with acute ST-segment elevation MI (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).1

Patients with acute ST-segment elevation myocardial infarction (STEMI) who were to be hospitalized within 6 hours of onset and were eligible to receive fibrinolytic therapy were randomized in a 1:1 ratio to receive either LOVENOX or unfractionated heparin (UFH). All patients were treated with aspirin for a minimum of 30 days. A total of 20,479 patients, mean age 60 years, were randomized. Rates of major hemorrhage at 30 days were 2.1% and 1.4% in the LOVENOX and UFH groups, respectively.

Relative risk reduction of combined endpoint of MI or death clinical study results

aThe NNT and the benefit/risk profile were not prespecified analyses in the trials and were calculated using the reported ARR results.3


STEMI
safety information
Thrombolytic therapy (fibrin-specific or non-fibrin-specific)1
When LOVENOX is administered in conjunction with a thrombolytic
LOVENOX should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy
Patients transitioned to PCI1
If the last LOVENOX subcutaneous administration was given:
<8 hours before balloon inflation
>8 hours before balloon inflation




No additional dosing needed

Administer LOVENOX 0.3 mg/kg intravenous bolus

All patients should receive ASA as soon as they are identified as having STEMI, and maintained with 75 mg to 325 mg once daily, unless contraindicated.

The only adverse reaction that occurred at a rate of at least 0.5% in the LOVENOX group was thrombocytopenia (1.5%).

LOVENOX is indicated for the prophylaxis of ischemic complications of unstable angina (UA) and non–Q-wave MI when concurrently administered with aspirin.

STEMI guideline

2013 ACCF/AHA Guidelines on the management of ST-elevation MI recommend the use of enoxaparin as adjunctive anticoagulant therapy with fibrinolysis when PCI is not possible and when PCI is delayed.8


Learn more about dosing
for LOVENOX across all
indications.

GET DOSING INFORMATION

LOVENOX has an authorized generic
that is identical by design—Enoxaparin
Sodium injection from Winthrop US.

FIND OUT MORE
+
Important Safety Information
for LOVENOX®

Warning: spinal/epidural hematoma Epidural or spinal hematomas may occur in
patients who are anticoagulated with low